Next-Generation Topical Delivery for Infantile Dermatitis: Exploring the Therapeutic Potential of Solid Lipid Nanoparticles
Main Article Content
Abstract
Background. Infantile dermatitis, most commonly atopic in origin, affects an estimated 15–20% of children worldwide and imposes a substantial burden on quality of life and household finances. The infant skin barrier is structurally and functionally immature: the stratum corneum is roughly 30% thinner than in adults, transepidermal water loss is higher, and the body-surface-area-to-mass ratio is approximately 2.5–3 times greater. These features raise the risk of systemic exposure from topical therapy precisely in the population least able to tolerate it, and they constrain the safe use of the current standard of care.
Scope. This narrative review examines solid lipid nanoparticles (SLNs) and their second-generation counterparts, nanostructured lipid carriers (NLCs), as a topical delivery platform for infantile dermatitis. It covers carrier architecture and composition, production and characterization methodology, mechanisms of cutaneous delivery, the published formulation evidence for dermatitis-relevant actives, and the safety, regulatory and manufacturing considerations governing translation.
Key findings. SLNs deliver drug to the skin through three interacting mechanisms: formation of an occlusive lipid film that reduces transepidermal water loss and hydrates the stratum corneum, size-dependent surface contact and follicular deposition, and sustained release from a solid lipid matrix. Across the formulations reviewed — fluticasone propionate, tacrolimus, ebastine, etofenamate, ibuprofen, curcumin, resveratrol, quercetin and leflunomide — encapsulation consistently improved physical and photochemical stability and moderated the release profile relative to free drug. Where studies progressed to animal disease models, comparable or superior anti-inflammatory efficacy was achieved at substantially reduced doses, including an 8- to 16-fold dose reduction for etofenamate and ibuprofen.
Conclusion. The mechanistic case for SLN-based topical therapy in infantile dermatitis is coherent and is supported by consistent adult and adult-animal data. It is not, however, supported by pediatric evidence. No permeation study identified used infant or neonatal skin, no in vivo study used a neonatal or juvenile animal model, no clinical trial of an SLN formulation for infantile dermatitis was identified, and no regulatory authority has approved such a product. Until pediatric-specific pharmacokinetic, irritation and safety data are generated, SLN delivery for infantile dermatitis should be regarded as a mechanistically promising but clinically unproven strategy.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115–23.
Werfel T, Heratizadeh A, Aberer W, Ahrens F, Augustin M, Biedermann T, et al. S2k guideline on diagnosis and treatment of atopic dermatitis — short version. Allergo J Int. 2016;25:82–95.
Dhar S, Kanwar AJ. Epidemiology and clinical pattern of atopic dermatitis in a North Indian pediatric population. Pediatr Dermatol. 1998;15:347–51.
Sarkar R, Kanwar AJ. Clinico-epidemiological profile and factors affecting severity of atopic dermatitis in North Indian children. Indian J Dermatol. 2004;49:117–22.
Dhar S, Mandal B, Ghosh A. Epidemiology and clinical pattern of atopic dermatitis in 100 children seen in a city hospital. Indian J Dermatol. 2002;47:202–4.
Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG. Discovery of topical calcineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol. 2006;141(3):199–212. DOI: 10.1159/000095289.
Aschoff R, Schmitt J, Knuschke P, Koch E, Bräutigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832–6. DOI: 10.1111/j.1600-0625.2011.01335.x.
Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153(10):1036–42. DOI: 10.1001/jamadermatol.2017.2437.
Siegfried EC, Jaworski JC, Hebert AA. Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice. Am J Clin Dermatol. 2013;14(3):163–78. DOI: 10.1007/s40257-013-0020-1.
Stamatas GN, Nikolovski J, Mack MC, Kollias N. Infant skin physiology and development during the first years of life: a review of recent findings based on in vivo studies. Int J Cosmet Sci. 2011;33:17–24.
Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006;19:296–302.
Vitellaro-Zuccarello L, Cappelletti S, Dal Pozzo Rossi V, Sari-Gorla M. Stereological analysis of collagen and elastic fibers in the normal human dermis: variability with age, sex, and body region. Anat Rec. 1994;238:153–62.
Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol. 2008;128(7):1728–36. DOI: 10.1038/sj.jid.5701239.
Silverman RA. Pediatric dermatology. In: Schachner LA, Hansen RC, editors. 4th ed. Philadelphia (PA): Elsevier; 2014.
Oranges T, Dini V, Romanelli M. Skin physiology of the neonate and infant: clinical implications. Adv Wound Care (New Rochelle). 2015;4:587–95.
Luger TA, Lahfa M, Fölster-Holst R, Gulliver WP, Allen R, Molloy S, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15:169–78.
Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol. 2008;158:801–7.
Fukuie T, Hirakawa S, Narita M, Nomura I, Matsumoto K, Tokura Y, et al. Potential preventive effects of proactive therapy on sensitization in moderate to severe childhood atopic dermatitis: a randomized, investigator-blinded, controlled study. J Dermatol. 2016;43:1283–92.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary. 69th ed. London: BMA and RPS;
Hong E, Smith S, Fischer G. Evaluation of the atrophogenic potential of topical corticosteroids in pediatric dermatology patients. Pediatr Dermatol. 2011;28:393–6.
Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135:597–606.
Ashcroft DM, Dimmock P, Garside R, Stein K, Williams HC. Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomized controlled trials. BMJ. 2005;330:516.
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II. J Eur Acad Dermatol Venereol. 2012;26:1176–93.
Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16:75.
Nakamura M, Uemura K, Nemoto O, Miyachi Y. Evaluation of an optimal method for topical application of moisturizer. Skin Res. 2006;5:311.
Grimalt R, Mengeaud V, Cambazard F; Study Investigators’ Group. The steroid-sparing effect of an emollient therapy in infants with atopic dermatitis: a randomized controlled study. Dermatology. 2007;214:61–7.
Hon KL, Ching GK, Leung TF, Choi CY, Lee KK, Ng PC. Estimating emollient usage in patients with eczema. Clin Exp Dermatol. 2010;35:22–6.
Draelos ZD. An evaluation of prescription device moisturizers. J Cosmet Dermatol. 2009;8:40–3.
Panahi Y, Davoudi SM, Sahebkar A, Beiraghdar F, Dadjo Y, Feizi I, et al. Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: a randomized double-blind clinical trial. Cutan Ocul Toxicol. 2012;31:95–103.
Intahphuak S, Khonsung P, Panthong A. Anti-inflammatory, analgesic and antipyretic activities of virgin coconut oil. Pharm Biol. 2010;48(2):151–7. DOI: 10.3109/13880200903062614.
Akihisa T, Kojima N, Kikuchi T, Yasukawa K, Tokuda H, Masters ET, et al. Anti-inflammatory and chemopreventive effects of triterpene cinnamates and acetates from shea fat. J Oleo Sci. 2010;59:273–80.
Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol. 2013;31:91.
Richardson M. Understanding the structure and function of the skin. Nurs Times. 2003;99:46–8.
Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta. 2006;1758:2080–95.
de Souza Guedes L, Martinez RM, Bou-Chacra NA, Velasco MVR, Rosado C, Baby AR. An overview on topical administration of carotenoids and coenzyme Q10 loaded in lipid nanoparticles. Antioxidants (Basel). 2021;10:1034.
Fore J. A review of skin and the effects of aging on skin structure and function. Ostomy Wound Manage. 2006;52:24–35.
Bouwstra J. Structure of the skin barrier and its modulation by vesicular formulations. Prog Lipid Res. 2003;42:1–36.
Bukhari SI, Imam SS, Ahmad MZ, Vuddanda PR, Alshehri S, Mahdi WA, et al. Recent progress in lipid nanoparticles for cancer theranostics: opportunity and challenges. Pharmaceutics. 2021;13:840.
Garg A, Sharma GS, Goyal AK, Ghosh G, Si SC, Rath G. Recent advances in topical carriers of anti-fungal agents. Heliyon. 2020;6:e04663.
DeLouise LA. Applications of nanotechnology in dermatology. J Invest Dermatol. 2012;132:964–75.
Lason E. Topical administration of terpenes encapsulated in nanostructured lipid-based systems. Molecules. 2020;25:5758.
Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv. 2012;9:497–508.
Nyström AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J Control Release. 2012;161:403–8.
Viegas C, Patrício AB, Prata JM, Nadhman A, Chintamaneni PK, Fonte P. Solid lipid nanoparticles vs. nanostructured lipid carriers: a comparative review. Pharmaceutics. 2023;15(6):1593. DOI: 10.3390/pharmaceutics15061593.
Munir M, Zaman M, Waqar MA, Khan MA, Alvi MN. Solid lipid nanoparticles: a versatile approach for controlled release and targeted drug delivery. J Liposome Res. 2024;34(2):335–48. DOI: 10.1080/08982104.2023.2268711.
Gao S, McClements DJ. Formation and stability of solid lipid nanoparticles fabricated using phase inversion temperature method. Colloids Surf A Physicochem Eng Asp. 2016;499:79–87. DOI:
10.1016/j.colsurfa.2016.03.065.
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target. 2012;20(10):813–30. DOI: 10.3109/1061186X.2012.716845.
Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MHA, Silva AM, et al. Current state-of-art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv. 2012;2012:750891. DOI: 10.1155/2012/750891.
Wei CC, Ge ZQ. Influence of electrolyte and poloxamer 188 on the aggregation kinetics of solid lipid nanoparticles (SLNs). Drug Dev Ind Pharm. 2012;38(9):1084–9. DOI: 10.3109/03639045.2011.640331.
Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54(Suppl 1):S131–55. DOI: 10.1016/S0169-409X(02)00118-7.
Stefanov S, Andonova V, Peneva P, Kassarova M. Technological strategies for the preparation of lipid nanoparticles: an updated review. Pharmacia. 2023;70(3):449–63. DOI: 10.3897/pharmacia.70.e108119.
Subroto E, Andoyo R, Indiarto R. Solid lipid nanoparticles: review of the current research on encapsulation and delivery systems for active and antioxidant compounds. Antioxidants (Basel). 2023;12(3):633. DOI: 10.3390/antiox12030633.
Khairnar SV, Pagare P, Thakre A, Nambiar AR, Junnuthula V, Abraham MC, et al. Review on the scale-up methods for the preparation of solid lipid nanoparticles. Pharmaceutics. 2022;14(9):1886. DOI: 10.3390/pharmaceutics14091886.
Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev. 2001;47(2–3):165–96. DOI: 10.1016/S0169-409X(01)00105-3.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery — a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–77. DOI: 10.1016/S0939-6411(00)00087-4.
Mardhiah Adib Z, Ghanbarzadeh S, Kouhsoltani M, Yari Khosroshahi A, Hamishehkar H. The effect of particle size on the deposition of solid lipid nanoparticles in different skin layers: a histological study. Adv Pharm Bull. 2016;6(1):31–6. DOI: 10.15171/apb.2016.06.
Souto EB, Müller RH. Cosmetic features and applications of lipid nanoparticles (SLN, NLC). Int J Cosmet Sci. 2008;30(3):157–65. DOI: 10.1111/j.1468-2494.2008.00433.x.
Liu M, Wen J, Sharma M. Solid lipid nanoparticles for topical drug delivery: mechanisms, dosage form perspectives, and translational status. Curr Pharm Des. 2020;26(27):3203–17. DOI:
10.2174/1381612826666200526145706.
Pardeike J, Hommoss A, Müller RH. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int J Pharm. 2009;366(1–2):170–84. DOI: 10.1016/j.ijpharm.2008.10.003.
Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev. 2007;59(6):478–90. DOI: 10.1016/j.addr.2007.04.007.
Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8. DOI: 10.1038/nbt.1504.
Hadgraft J, Lane ME. Skin permeation: the years of enlightenment. Int J Pharm. 2005;305(1–2):2–12. DOI: 10.1016/j.ijpharm.2005.07.014.
Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14(2):101–14. DOI: 10.1016/S0928-0987(01)00167-1.
Wissing SA, Müller RH. Solid lipid nanoparticles as carrier for sunscreens: in vitro release and in vivo skin penetration. J Control Release. 2002;81(3):225–33. DOI: 10.1016/S0168-3659(02)00056-1.
Vogt A, Mandt N, Lademann J, Schaefer H, Blume-Peytavi U. Follicular targeting: distribution of fluorescent dyes in the hair follicles of human scalp skin. Eur J Pharm Biopharm. 2006;64(2):223–30.
Stamatas GN, Nikolovski J, Luedtke MA, Kollias N, Wiegand BC. Infant skin microstructure assessed in vivo differs from adult skin in organization and at the cellular level. Pediatr Dermatol. 2010;27(2):125–31. DOI: 10.1111/j.1525-1470.2009.00973.x.
Wissing SA, Müller RH. The influence of the crystallinity of lipid nanoparticles on their occlusive properties. Int J Pharm. 2002;242(1–2):377–9. DOI: 10.1016/S0378-5173(02)00220-X.
Üner M, Wissing SA, Yener G, Müller RH. Skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles and nanostructured lipid carriers incorporated into hydrogel. Pharmazie. 2005;60(10):751–5.
Telofski LS, Morello AP 3rd, Mack Correa MC, Stamatas GN. The infant skin barrier: can we preserve, protect, and enhance the barrier? Dermatol Res Pract. 2012;2012:198789. DOI: 10.1155/2012/198789.
Chiou YB, Blume-Peytavi U. Stratum corneum maturation: a review of neonatal skin function. Skin Pharmacol Physiol. 2004;17(2):57–66. DOI: 10.1159/000076015.
Kalia YN, Nonato LB, Lund CH, Guy RH. Development of skin barrier function in premature infants. J Invest Dermatol. 1998;111(2):320–6. DOI: 10.1046/j.1523-1747.1998.00289.x.
Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol. 2005;18(5):209–19. DOI: 10.1159/000086666.
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. DOI: 10.1186/1556-276X-8-102.
Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN, et al. Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules. 2020;25(16):3731. DOI:
10.3390/molecules25163731.
Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22–36. DOI: 10.1016/j.jconrel.2014.04.015.
Abu-Huwaij R, Alkarawi A, Salman D, Alkarawi F. Exploring the use of niosomes in cosmetics for efficient dermal drug delivery. Pharm Dev Technol. 2023;28(7):708–18. DOI: 10.1080/10837450.2023.2233613.
Pham DTT, Tran PHL, Tran TTD. Development of solid dispersion lipid nanoparticles for improving skin delivery. Saudi Pharm J. 2019;27(7):1019–24. DOI: 10.1016/j.jsps.2019.08.004.
Amasya G, Badilli U, Sengel-Turk CT, Onay-Besikci A, Aksu B, Tarimci N. Development and in vivo evaluation of a novel semi-solid nanostructured lipid carrier of fluticasone propionate for the treatment of atopic dermatitis using a quality by design approach. J Drug Deliv Sci Technol. 2025;114:107491.
Khan AS, Shah KU, Al Mohaini M, Alsalman AJ, Al Hawaj MA, Alhashem YN, et al. Tacrolimus-loaded solid lipid nanoparticle gel: formulation development and in vitro assessment for topical applications. Gels. 2022;8(2):129. DOI: 10.3390/gels8020129.
Kazim T, Tariq A, Usman M, Ayoob MF, Khan A. Chitosan hydrogel for topical delivery of ebastine loaded solid lipid nanoparticles for alleviation of allergic contact dermatitis. RSC Adv. 2021;11(59):37413–25. DOI: 10.1039/D1RA06283B.
Mancini G, Gonçalves LMD, Marto J, Carvalho FA, Simões S, Ribeiro HM, et al. Increased therapeutic efficacy of SLN containing etofenamate and ibuprofen in topical treatment of inflammation. Pharmaceutics. 2021;13(3):328. DOI: 10.3390/pharmaceutics13030328.
Cassano R, Serini S, Curcio F, Trombino S, Calviello G. Preparation and study of solid lipid nanoparticles based on curcumin, resveratrol and capsaicin containing linolenic acid. Pharmaceutics. 2022;14(8):1593. DOI: 10.3390/pharmaceutics14081593.
Bose S, Du Y, Takhistov P, Michniak-Kohn B. Formulation optimization and topical delivery of quercetin from solid lipid based nanosystems. Int J Pharm. 2013;441(1–2):56–66. DOI:
10.1016/j.ijpharm.2012.12.013.
Tangjidapichai C, Tadtong S, Chittasupho C, Samee W. Preparation of quercetin-loaded lipid nanoparticle-embedded hydrogels and stability studies. Molecules. 2026;31(14):2539. DOI:
10.3390/molecules31142539.
Caddeo C, Díez-Sales O, Pons R, Fernàndez-Busquets X, Fadda AM, Manconi M. Topical anti-inflammatory potential of quercetin in lipid-based nanosystems: in vivo and in vitro evaluation. Pharm Res. 2014;31(4):959–68. DOI: 10.1007/s11095-013-1215-0.
Alhelal HM, Mehta S, Kadian V, Kakkar V, Tanwar H, Rao R, et al. Solid lipid nanoparticles embedded hydrogels as a promising carrier for retarding irritation of leflunomide. Gels. 2023;9(7):576. DOI:
10.3390/gels9070576.
Lazov C, Yoncheva K, Slavkova M. The significance of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) in the treatment of atopic dermatitis. Sci Pharm. 2026;94(1):19. DOI:
10.3390/scipharm94010019.
Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, et al. SLN and NLC for topical, dermal, and transdermal drug delivery. Expert Opin Drug Deliv. 2020;17(3):357–77. DOI:
10.1080/17425247.2020.1727883.
Siddique MI, Katas H, Amin MCI, Ng SF, Zulfakar MH, Jamil A. In vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis. Int J Pharm. 2016;507(1–2):72–82. DOI: 10.1016/j.ijpharm.2016.05.005.
European Medicines Agency. ICH E11(R1) guideline on clinical investigation of medicinal products in the pediatric population: addendum. Amsterdam: EMA; 2017. EMA/CPMP/ICH/2711/1999.
US Food and Drug Administration. E11A pediatric extrapolation: guidance for industry. Silver Spring (MD): FDA; 2024.
Zisowsky J, Krause A, Dingemanse J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics. 2010;2(4):364–88. DOI: 10.3390/pharmaceutics2040364.
Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced Ostwald ripening. WO patent WO2019055525A1. 2019 Mar 21.
Khames A, Khaleel MA, El-Badawy MF, El-Nezhawy AOH. Natamycin solid lipid nanoparticles — sustained ocular delivery system of higher corneal penetration against deep fungal keratitis: preparation and optimization. Int J Nanomedicine. 2019;14:2515–31. DOI: 10.2147/IJN.S190502.
Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat. 2020;30(3):179–94. DOI:
10.1080/13543776.2020.1720649.
ClinicalTrials.gov. Topical NanoDox for atopic dermatitis. Bethesda (MD): National Library of Medicine. Identifier NCT02910011.
Waligóra-Dziwak K, Dańczak-Pazdrowska A, Jenerowicz D. A comprehensive review of biologics in phase III and IV clinical trials for atopic dermatitis. J Clin Med. 2024;13(14):4001. DOI: 10.3390/jcm13144001.
Muthu MS, Wilson B. Challenges posed by the scale-up of nanomedicines. Nanomedicine (Lond). 2012;7(3):307–9. DOI: 10.2217/nnm.12.3.
Mehta M, Bui TA, Yang X, Aksoy Y, Goldys EM, Deng W. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3(6):600–19. DOI: 10.1021/acsmaterialsau.3c00032.
Attama AA, Momoh MA, Builders PF. Lipid nanoparticulate drug delivery systems: a revolution in dosage form design and development. In: Ficai A, Grumezescu AM, editors. Nanostructures for oral medicine. London: IntechOpen; 2012. DOI: 10.5772/50486.
Nguyen VH, Thuy VN, Van TV, Dao AH, Lee BJ. Nanostructured lipid carriers and their potential applications for versatile drug delivery via oral administration. OpenNano. 2022;8:100064. DOI:
10.1016/j.onano.2022.100064.
Malik S, Rehman AU, Khan MFA, Ahmed N, Al Nasir MH. Solid lipid nanoparticles based topical hydrogel for potential treatment of infantile hemangioma. BioNanoScience. 2024;14(3):2964–75. DOI:
10.1007/s12668-024-01569-9.
Ebrahimian K, Dabbagh Moghaddam F, Tavangari SM. Next-generation atopic dermatitis treatments based on nanotechnology as an effective and low-side-effect solution. Oxford Open Mater Sci. 2026;6(1):itag003. DOI: 10.1093/oxfmat/itag003